CEO Interview 27 April, page-11

Vrs37, your credibility is not improved when you make stupid statements.

From the recent quarterly report:

• IONIC-1 is an Australian Phase 1b/2a trial in patients with advanced solid cancers involving the use of Veyonda to reduce resistance to the PD-1 inhibitor, nivolumab (Opdivoâ), owned by Bristol Myers Squibb (BMS). Noxopharm and BMS are co-sponsors of this trial

• The Company believes the LuPIN program has been a good investment, delivering further proof-of-concept evidence of Veyonda boosting the effectiveness of another anti-cancer treatment, and all at low cost thanks to Novartis co-sponsoring